Cerus (CERS) Receiving Somewhat Favorable Press Coverage, Analysis Finds

Share on StockTwits

News articles about Cerus (NASDAQ:CERS) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cerus earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.0251715581892 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Cerus stock opened at $7.74 on Wednesday. The company has a current ratio of 5.03, a quick ratio of 4.57 and a debt-to-equity ratio of 0.29. Cerus has a 1 year low of $2.43 and a 1 year high of $8.05. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -13.82 and a beta of 1.60.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. Cerus had a negative net margin of 76.37% and a negative return on equity of 82.60%. The company had revenue of $15.42 million for the quarter, compared to analysts’ expectations of $13.58 million. During the same period in the prior year, the business earned ($0.16) EPS. The firm’s quarterly revenue was up 61.8% on a year-over-year basis. equities research analysts forecast that Cerus will post -0.44 earnings per share for the current fiscal year.

A number of research firms have recently commented on CERS. Zacks Investment Research cut shares of Cerus from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price target on shares of Cerus in a report on Thursday, August 2nd. BidaskClub cut shares of Cerus from a “buy” rating to a “hold” rating in a report on Wednesday, August 22nd. ValuEngine upgraded shares of Cerus from a “buy” rating to a “strong-buy” rating in a report on Friday, June 1st. Finally, Cowen set a $10.00 target price on shares of Cerus and gave the stock a “buy” rating in a report on Friday, August 3rd. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $8.13.

In other news, insider Richard J. Benjamin sold 35,416 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $7.20, for a total value of $254,995.20. Following the sale, the insider now directly owns 35,416 shares in the company, valued at approximately $254,995.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gail Schulze sold 52,500 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were sold at an average price of $6.65, for a total transaction of $349,125.00. Following the completion of the sale, the director now owns 40,986 shares in the company, valued at $272,556.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,699 shares of company stock worth $998,490. 6.80% of the stock is owned by company insiders.

About Cerus

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Featured Article: Stop Order Uses For Individual Investors

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply